

Domain Swapping in Human α A and α B Crystallins Affects Oligomerization and Enhances Chaperone-like Activity*

Received for publication, April 18, 2000, and in revised form, April 27, 2000
Published, JBC Papers in Press, April 28, 2000, DOI 10.1074/jbc.M003307200

L. V. Siva Kumar‡ and Ch. Mohan Rao§

From the Centre for Cellular and Molecular Biology, Hyderabad 500007, India

α A and α B crystallins, members of the small heat shock protein family, prevent aggregation of proteins by their chaperone-like activity. These two proteins, although very homologous, particularly in the C-terminal region, which contains the highly conserved “ α -crystallin domain,” show differences in their protective ability toward aggregation-prone target proteins. In order to investigate the differences between α A and α B crystallins, we engineered two chimeric proteins, α ANBC and α BNAC, by swapping the N-terminal domains of α A and α B crystallins. The chimeras were cloned and expressed in *Escherichia coli*. The purified recombinant wild-type and chimeric proteins were characterized by fluorescence and circular dichroism spectroscopy and gel permeation chromatography to study the changes in secondary, tertiary, and quaternary structure. Circular dichroism studies show structural changes in the chimeric proteins. α BNAC binds more 8-anilino-naphthalene-1-sulfonic acid than the α ANBC and the wild-type proteins, indicating increased accessible hydrophobic regions. The oligomeric state of α ANBC is comparable to wild-type α B homoaggregate. However, there is a large increase in the oligomer size of the α BNAC chimera. Interestingly, swapping domains results in complete loss of chaperone-like activity of α ANBC, whereas α BNAC shows severalfold increase in its protective ability. Our findings show the importance of the N- and C-terminal domains of α A and α B crystallins in subunit oligomerization and chaperone-like activity. Domain swapping results in an engineered protein with significantly enhanced chaperone-like activity.

α -Crystallin, a major lens protein having homology with small heat shock proteins (1–3), prevents aggregation of other proteins like a molecular chaperone (4). We had earlier shown that α -crystallin can prevent photo-aggregation of γ -crystallin, which may have relevance in cataractogenesis (5). By using various non-thermal modes of aggregation, it was shown that chaperone-like activity of α -crystallin is temperature-dependent. A structural perturbation above 30 °C enhances this activity severalfold (6, 7). In order to probe the molecular mechanism of the chaperone-like activity and its enhancement upon structural perturbation, we have been studying α -crystallin and its constituent subunits. Our recent study on the α A and

α B homoaggregates showed that, despite high sequence homology, these proteins differ in their stability, chaperone-like activity, and the temperature dependence of this activity (8). This study also indicated different roles for the two proteins in the α -crystallin heteroaggregate in the eye lens and as separate proteins in non-lenticular tissues. Several investigators have introduced mutations in α A and α B crystallins to gain an insight into the structure-function relation (9–12). Derham and Harding in their recent review (13) list about 30 site-directed mutations from different laboratories. These mutations either result in some decrease or no change in the protective ability. It is interesting to note that point mutations in both α A and α B crystallin, R116C and R120G, respectively, result in significant loss of activity and are associated with human diseases (14–19).

Human α A and α B crystallins are coded by three exons (20, 21) and are thought to have arisen due to gene duplication. They share high sequence homology with the small heat shock proteins, which are found in all organisms, from prokaryotes to humans (22). α A and α B crystallins are constitutively expressed during normal growth and development. α A crystallin is expressed predominantly in the eye lens with small amounts being present in spleen and thymus (23), whereas α B crystallin is expressed not only in the eye lens, but also in several other tissues such as heart, skeletal muscle, placenta, lung, and kidney (24, 25). The main function of these proteins in the lens appears to provide transparency and prevent precipitation by binding to other aggregation-prone proteins. In the lens, α A and α B crystallins exist as heteroaggregates of approximately 800 kDa. Both the recombinant α A and α B crystallins exist as high molecular mass oligomeric proteins of approximately 640 and 620 kDa, respectively (26). The size of these proteins can vary a little depending on the pH and ionic strength, and they differ in their structure, function, tissue expression, and abnormal deposition in disease.


α B crystallin has a heat shock element upstream to the gene and is induced during stress (3, 28). Apart from maintaining lens transparency, its *in vivo* functions include interaction with intermediate filaments (29) and regulation of cytomorphological rearrangements during development (30). α B crystallin is hyperexpressed in neurological disorders such as Alzheimer's disease, Creutzfeldt-Jacob disease, and Parkinson's disease (31–33).

The charged C-terminal domain is conserved in all the members of the small heat shock protein family, whereas the hydrophobic N-terminal domain is variable in length and sequence similarity (34). The N- and C-terminal domains are thought to form two structural domains with an exposed C-terminal extension (35). To investigate the role of the N-terminal domains in the differential structural and functional properties of human α A and α B crystallins, we have swapped their N-terminal domains coded by exon 1. A unique *Xmn*I restriction site at the beginning of the α -crystallin domain in a 20-

* This work was supported in part by the Department of Biotechnology, Government of India. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

‡ Recipient of a senior research fellowship from the University Grants Commission, Government of India.

§ To whom correspondence should be addressed. Tel.: 91-40-717-2241; Fax: 91-40-717-1195; E-mail: mohan@ccmb.ap.nic.in.



nucleotide stretch in exon 2, with 100% sequence identity in human α A and α B crystallin genes, has been used to create chimeric proteins α ANBC and α BNAC. We have used biophysical methods to study the structural and functional properties of wild-type α A and α B crystallins as well as the chimeras in order to get an insight into the effect of swapping and the role of the N-terminal domain in oligomerization and chaperone-like activity.

EXPERIMENTAL PROCEDURES

Construction of Human Chimeric α A and α B Crystallins

α ANBC Chimera—The 235-base pair *Nde*I-*Xmn*I fragment of pCR2.1- α A plasmid (16) was ligated to the 384-base pair *Xmn*I-*Hind*III fragment of pCR2.1- α B plasmid (16) to generate chimeric coding region of α ANBC. The α ANBC chimera with *Nde*I-*Hind*III overhangs was then ligated to *Nde*I-*Hind*III-linearized expression vector pET21a (Novagen) to produce pET21a- α ANBC.

α BNAC Chimera—The 247-base pair *Nde*I-*Xmn*I fragment of pCR2.1- α B was ligated to the 446-base pair *Xmn*I-*Hind*III fragment of pCR2.1- α A to generate the chimeric coding region of α BNAC. The α BNAC chimera with *Nde*I-*Hind*III overhangs was ligated to *Nde*I-*Hind*III-linearized pET21a to produce pET21a- α BNAC.

Sequencing of Human Chimeric α ANBC and α BNAC Crystallins

Sequencing was done with T7 promoter primer using the dye terminator cycle sequencing kit (Perkin-Elmer) in an 3700 ABI automated DNA sequencer. The coding regions of both the α ANBC and α BNAC chimeras were found to be mutationless with no change in the reading frame.

Overexpression and Purification of Human Wild-type and Chimeric α A and α B Crystallins

The expression plasmids (pET21a- α Awt, pET21a- α Bwt, pET21a- α ANBC, and pET21a- α BNAC) were transformed into competent *Escherichia coli* BL21(DE3) cells. Growth, induction, lysis of cells, and purification of chimeric proteins was done as described for recombinant wild-type α A and α B crystallins (26).

FPLC¹ Gel Permeation Chromatography

Multimeric sizes of the wild-type and chimeric proteins were evaluated on Superose-6 HR 10/30 prepac column (dimensions: 10 × 300 mm, bed volume: 24 ml) with reference to high molecular mass standards (Sigma). Standards used were thyroglobulin (669 kDa), ferritin (440 kDa), and catalase (232 kDa).

Fluorescence Measurements

Intrinsic Fluorescence—Intrinsic fluorescence spectra of wild-type and chimeric proteins were recorded using a Hitachi F-4000 fluores-

cence spectrophotometer with the excitation wavelength of 295 nm. The excitation and emission band passes were set at 5 and 3 nm, respectively. Intrinsic fluorescence spectra were recorded using 0.2 mg/ml protein in 10 mM phosphate buffer, which was incubated at 37 °C for 10 min.

8-Anilino-1-naphthalenesulfonic Acid (ANS) Binding—Wild-type and chimeric proteins (0.2 mg/ml) in 10 mM phosphate buffer, pH 7.4, containing 100 mM NaCl were equilibrated at 37 °C in the sample holder of Hitachi F-4000 fluorescence spectrophotometer using a Julabo thermostated water bath for 10 min. To these protein samples, 20 μ l of 10 mM ANS was added. Fluorescence spectra were recorded with an excitation wavelength of 365 nm. The excitation and emission band passes were 5 and 3 nm, respectively.

Circular Dichroism Studies

Circular dichroism spectra were recorded using a Jasco J-715 spectropolarimeter. All spectra reported are the average of 5 accumulations. Far- and near-UV CD spectra were recorded using 0.05- and 1-cm pathlength cuvettes, respectively.

Assay for Protein Aggregation

Chaperone-like activity of the wild-type and chimeric proteins was studied by the insulin aggregation assay (6, 36). The extent of protection by the wild-type α A and α B crystallins and the chimeric proteins was studied by incubating insulin (0.2 mg/ml) with various concentrations of the wild-type and chimeric proteins for 10 min at 37 °C. Aggregation was initiated by the addition of 20 μ l of 1 M dithiothreitol (DTT) after the incubation.

RESULTS AND DISCUSSION

Construction and Expression of the Chimeric Human α A and α B Crystallins—Human α A and α B crystallin genes have a unique site for the restriction enzyme *Xmn*I at the beginning of exon 2. A 20 nucleotide stretch at the *Xmn*I site in both α A and α B crystallins has 100% sequence identity. Swapping of the domains does not disturb the reading frame (Fig. 1). Since *Xmn*I site is slightly into the exon II, the excised N-terminal fragment has additional 15 amino acids. Of the 15 amino acids, 8 are identical and the rest are chemically conserved. Ligation of the N-terminal domain of α A crystallin with the C-terminal region of α B crystallin results in the chimeric polypeptide α ANBC crystallin, which is 171 amino acids long. Similarly, the ligation of the N-terminal region of α B crystallin with C-terminal domain of α A crystallin creates polypeptide α BNAC crystallin that is 177 amino acids long. Henceforth, the chimeras are referred to as α ANBC and α BNAC. Overexpression and purification of the chimeric proteins was carried out as described earlier for the wild-type proteins. The wild-type and chimeric proteins were purified to greater than 95% homoge-

¹ The abbreviations used are: FPLC, fast protein liquid chromatography; ANS, 8-anilino-1-naphthalenesulfonic acid; DTT, dithiothreitol.




FIG. 2. FPLC gel filtration profiles of wild-type αA and αB crystallins and chimeric proteins on a Superose-6 column. A, wild-type αA crystallin (—) and wild-type crystallin αB (---). B, $\alpha ANBC$ chimera (—) and $\alpha BNAC$ chimera (---). The void volume (a) and elution positions of thyroglobulin (669 kDa) (b), ferritin (440 kDa) (c), and catalase (232 kDa) (d) are also indicated.

neity, as judged by SDS-polyacrylamide gel electrophoresis (data not shown), and moved as ~ 20 -kDa proteins as expected. Interestingly, when $\alpha ANBC$ is eluted from a Mono Q ion exchange column with a 0–2 M NaCl gradient, it elutes at ~ 100 mM NaCl like the wild-type αB crystallin. On the other hand, $\alpha BNAC$ elutes at ~ 350 mM NaCl, similar to wild-type αA crystallin. The number of positively and negatively charged amino acids are identical in wild-type αA crystallin and $\alpha BNAC$ (Arg+Lys = 20; Asp+Glu = 25) and in wild-type αB crystallin and $\alpha ANBC$ (Arg+Lys = 24; Asp+Glu = 25). A recently proposed model for α -crystallin suggests that the hydrophobic N-terminal domain is mostly buried in the oligomer (37). Thus, the C-terminal domain may largely determine the surface charge distribution of the proteins. This could be one of the reasons for the similarity in Mono Q elution profiles of wild-type proteins and chimeras that contain C-terminal regions identical to those of the wild-type proteins.

Superose-6 Gel Permeation Chromatography—To investigate the consequences of domain swapping on the molecular masses, chimeric and wild-type proteins were chromatographed on a FPLC Superose-6 gel filtration column (Fig. 2). The average molecular masses of wild-type αA and αB crystallins were observed to be ~ 640 and ~ 620 kDa, respectively. These sizes are consistent with earlier reports (16, 26). The chimera $\alpha ANBC$ elutes at the same elution volume as that of wild-type αB with an apparent molecular mass of ~ 620 kDa. However the $\alpha BNAC$ chimera oligomerizes into large polydisperse aggregates, with species exceeding 2000 kDa. This finding shows an important difference in αA and αB crystallins. The $\alpha ANBC$ chimera consisting of the N-terminal domain of αA crystallin and the C-terminal domain of αB crystallin still possesses the oligomer size of wild-type αA and αB crystallins. Thus, it appears that the N-terminal domain of αB crystallin can be replaced by the N-terminal domain of αA crystallin with no alteration in the oligomeric status. However, the N-terminal domain of αB crystallin in fusion with the C-terminal domain of αA crystallin forms very large aggregates, probably due to altered packing of the subunits with an increase in intersub-




FIG. 3. Intrinsic fluorescence spectra of wild-type αA crystallin (○), wild-type αB crystallin (●), $\alpha ANBC$ (△), and $\alpha BNAC$ (▲).

unit interaction. This kind of increase in the oligomer size was earlier observed in the R116C mutant of αA crystallin (15). The monomer sizes of the proteins of the small heat shock protein family range from 12 to 43 kDa. Almost all members of this family multimerize to form large aggregates, ranging in size from 400 to 800 kDa with only one exception till date; sHSP 12.6 of *Caenorhabditis elegans*, which has the shortest N- and C-terminal domains, is monomeric (38). The N-terminal domain is variable in both length and sequence in the sHSP superfamily, which might be responsible for the varying multimeric sizes. Bova *et al.* (27) showed that sequential truncation from the N terminus of αA crystallin reduces oligomeric size. In the present study, the sequence length of the swapped N-terminal domain between αA and αB crystallin is similar, so the variation in sequence of this domain is likely to be responsible for the differential multimerization of the chimeric proteins.

Intrinsic and ANS Fluorescence—The emission maximum of tryptophan is highly sensitive to solvent polarity and depends on the accessibility of tryptophan residues to the aqueous phase. Fig. 3 shows the intrinsic fluorescence spectra of wild-type and chimeric proteins. The intrinsic fluorescence spectra of the wild-type αB crystallin and $\alpha BNAC$ are similar. Both the tryptophans are present in the N-terminal domain, which are likely to be in a similar environment even after domain swapping. A slight blue shift, noticeable in the red region of the emission profile of $\alpha BNAC$, compared with the wild-type αB crystallin suggests that the tryptophans in the chimera are marginally less solvent accessible. The intrinsic fluorescence spectra of the lone tryptophan of wild-type αA crystallin, which is present in the N-terminal domain, and $\alpha ANBC$ are similar, indicating no alteration of the tryptophan environment in the chimeric $\alpha ANBC$ protein with respect to the wild-type αA crystallin. Fig. 4 shows the spectra of ANS in the presence of wild-type and chimeric proteins. ANS fluorescence spectra show marked differences in emission intensity with no apparent change in emission maxima. The $\alpha ANBC$ chimera binds the least amount of ANS among all the proteins compared. The $\alpha BNAC$ chimera, on the other hand, binds ANS several times more when compared with wild-type αB crystallin, wild-type αA crystallin, and $\alpha ANBC$ chimera. This finding suggests that there are more hydrophobic regions accessible to ANS in the $\alpha BNAC$ chimera than in $\alpha ANBC$ chimera. The molecular basis for this finding is not yet clear. However, the gel permeation chromatography data together with ANS fluorescence suggest that $\alpha BNAC$ might be forming a large porous oligomer.

Circular Dichroism Measurements of Chimeric $\alpha ANBC$ and $\alpha BNAC$ Crystallins—Fig. 5 shows far-UV circular dichroism spectra of wild-type and chimeric proteins. CD spectra of wild-type αA and αB crystallins, shown in panel A, are comparable with the CD spectra of recombinant human αA and αB crys-




FIG. 4. The normalized fluorescence emission spectrum of ANS bound to wild-type αA crystallin (\circ), wild-type αB crystallin (\bullet), $\alpha ANBC$ (Δ), and $\alpha BNAC$ (\blacktriangle).




FIG. 5. Far-UV CD spectra of wild-type αA and αB crystallins and chimeric proteins. A, wild-type αA crystallin (\cdots) and wild-type αB crystallin (—). B, $\alpha ANBC$ (—) and $\alpha BNAC$ (\cdots). The samples were prepared in 50 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl and 1 mM EDTA.

tallins reported earlier (15, 16, 26). Both the spectra show characteristic β -sheet protein profile as expected. Chimeric proteins also show β -sheet CD profiles. The CD spectrum of $\alpha ANBC$ is comparable to the spectra of wild-type αA and αB crystallins. However, $\alpha BNAC$ shows increased ellipticity.

Near-UV CD spectra (Fig. 6) also show a similar trend. Spectra of wild-type αA and αB are comparable to earlier reported spectra for recombinant human αA and αB crystallins (15). The CD spectrum of the chimeric $\alpha ANBC$ is comparable to that of αB crystallin with increased chirality for $\alpha ANBC$. The CD spectrum of $\alpha BNAC$ on the other hand is comparable to that of wild-type αA crystallin.

Domain swapping results in some change in secondary and tertiary structure of $\alpha ANBC$ with observable change only in the secondary structure for $\alpha BNAC$.

Chaperone-like Activity—Insulin B-chain aggregates in the presence of DTT. At 37 °C a 1:1 (w/w) ratio of wild-type αA and αB crystallin to insulin prevented this aggregation completely. At ratios of 1:2 and 1:4, aggregation was prevented to lesser extents, as shown in Fig. 7 (panels A and B). Interestingly, the chimera $\alpha BNAC$ showed enhanced chaperone-like activity. The initial scatter value for $\alpha BNAC$ chimera without insulin was very high. The large molecular size of $\alpha BNAC$ could be respon-




FIG. 6. Near-UV CD spectra of wild-type αA and αB crystallins and chimeric proteins. A, wild-type αA crystallin (\cdots) and wild-type αB crystallin (—). B, $\alpha ANBC$ (—) and $\alpha BNAC$ (\cdots). The samples were prepared in 50 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl and 1 mM EDTA.




FIG. 7. Chaperone-like activity of wild-type αA and αB crystallins and chimeric proteins. A, effect of wild-type αA crystallin. DTT-induced aggregation of 0.2 mg/ml insulin alone (*Ins*) and in the presence of 1:1, 1:2, and 1:4 w/w wild-type αA crystallin:insulin, respectively. B, effect of wild-type αB crystallin. Panel shows aggregation of 0.2 mg/ml insulin alone (*Ins*) and in the presence of 1:1, 1:2, and 1:4 w/w wild-type αB crystallin:insulin, respectively. C, effect of $\alpha ANBC$ chimera. Panel shows aggregation of 0.2 mg/ml insulin alone (*Ins*) and in the presence of 1:2 and 1:1 w/w $\alpha ANBC$:insulin, respectively. D, effect of $\alpha BNAC$ chimera. Panel shows aggregation of 0.2 mg/ml insulin alone (*Ins*) and in the presence of 1:6, 1:8, 1:12, and 1:16 w/w $\alpha BNAC$:insulin, respectively.

sible for the high scatter. We had earlier observed a similar high initial scatter value for the R116C mutant of αA crystallin, which also forms a large aggregate (>2000 kDa) (16). The data were normalized to determine the protective ability of the $\alpha BNAC$ protein. At 37 °C complete protection was observed at a 1:6 w/w ratio of $\alpha BNAC$ to insulin. Significant protection was observed even at 1:8, 1:12, and 1:16 ratios of $\alpha BNAC$ to insulin (Fig. 7D). The $\alpha BNAC$ chimera shows 3–4-fold increase in the

chaperone-like activity compared with the wild-type proteins. α ANBC, in contrast, shows complete loss of chaperone-like activity. A 1:2 (w/w) ratio of α ANBC to insulin does not show any protective ability toward DTT-induced aggregation of insulin. Increasing the α ANBC ratios to 1:1 and 2:1 w/w with respect to insulin does not show any increase in protection (Fig. 7C). In fact, α ANBC promotes the aggregation process as observed by increased light scattering.

The swapped N-terminal domain (exon 1 encoded) is comparable in length between human α A and α B crystallins. There are some differences in the sequences in this region. One of the prominent differences is the increase in the number of proline residues. The N-terminal domain of α A crystallin contains 5 proline residues, whereas the same region for α B crystallin has 9 proline residues (two prolines in tandem). The swapping alters the number of proline residues in the chimeric proteins. α BNAC contains 9 prolines in its N-terminal domain, a gain of 4 prolines in comparison to the same region of wild-type α A crystallin. Far-UV CD spectrum shows some enhancement in the secondary structure. Whether the local secondary structural changes can alter the subunit topology and consequently intersubunit interactions remains to be investigated. Although we point out differences in the number of proline residues, there are other sequence variations, and marginal changes in predicted pI and the total length of the chimeric proteins. Clearly discernible changes are oligomeric status, accessible hydrophobic surfaces, and chaperone-like activity.

It is interesting to note that, despite being similar to wild-type α B crystallin in the aggregate molecular mass and circular dichroism spectra, the chimeric α ANBC possesses no chaperone-like activity. The most important difference between the two chimeric proteins is the accessible hydrophobicity. ANS, a hydrophobicity probe, very clearly distinguishes the two chimeric proteins. We believe that the lack of accessible surface hydrophobicity, probably due to altered subunit packing in α ANBC chimera, results in its loss of chaperone-like activity.

The enhanced chaperone-like activity of α BNAC chimera could be because of the exposure and availability of more hydrophobic surfaces when compared with the wild-type proteins. Increased ANS binding of the α BNAC chimera supports this possibility. We observed an increase in oligomeric size and chaperone-like activity in the case of the α BNAC chimera. However, the increase in size and enhancement of chaperone-like activity may not be necessarily correlated. The point mutation R116C in α A crystallin leads to increased oligomer size but results in significant loss of chaperone-like activity. Swapping the N-terminal domain between human α A and α B crystallins makes a more effective chaperone in the case of α BNAC chimera, whereas α ANBC chimera loses its protective abilities completely. To the best of our knowledge, this is the first report where a 3–4-fold increase in chaperone-like activity is observed. This phenomenon may have a therapeutic significance in diseases occurring due to protein misfolding.

Acknowledgments—We thank Dr. T. Ramakrishna for critical reading of the manuscript and Shradha Goenka for useful discussions.

REFERENCES

- Ingolia, T. D., and Craig, E. A. (1982) *Proc. Natl. Acad. Sci. U. S. A.* **79**, 2360–2364
- de Jong, W. W., Leunissen, J. A. M., Leenen, P. J. M., Zweers, A., and Veersteeg, M. (1988) *J. Biol. Chem.* **263**, 5141–5149
- Klemenz, R., Fröhli, E., Steiger, R. H., Schäfer, R., and Aoyama, A. (1991) *Proc. Natl. Acad. Sci. U. S. A.* **88**, 3652–3656
- Horwitz, J. (1992) *Proc. Natl. Acad. Sci. U. S. A.* **89**, 10449–10453
- Raman, B., and Rao, Ch. M. (1994) *J. Biol. Chem.* **269**, 27264–27268
- Raman, B., Ramakrishna, T., and Rao, Ch. M. (1995) *FEBS Lett.* **365**, 133–136
- Raman, B., and Rao, Ch. M. (1997) *J. Biol. Chem.* **272**, 23559–23564
- Datta, S. A., and Rao, Ch. M. (1999) *J. Biol. Chem.* **274**, 34773–34778
- Smulders, R. H. P. H., Merck, K. B., Aendeckerk, J., Horwitz, J., Takemoto, L., Slingsby, C., Bloemendal, H., and de Jong, W. W. (1995) *Eur. J. Biochem.* **232**, 834–838
- Andley, U. P., Mathur, S., Griest, T. A., and Petrash, J. M. (1996) *J. Biol. Chem.* **271**, 31973–31980
- Plater, M. L., Goode, D., and Crabbe, M. J. (1996) *J. Biol. Chem.* **271**, 28558–28566
- Muchowski, P. J., Wu, G. J. S., Liang, J. J. N., Adman, E. T., and Clark, J. I. (1999) *J. Mol. Biol.* **289**, 397–411
- Derham, B. K., and Harding, J. J. (1999) *Prog. Retin. Eye Res.* **18**, 463–509
- Vicart, P., Caron, A., Guicheney, P., Li, Z., Prévost, M. C., Faure, A., Chateau, D., Chapon, F., Tomé, F., Dupret, J. M., Paulin, D., and Fardeau, M. (1998) *Nat. Genet.* **20**, 92–95
- Bova, M. P., Yaron, O., Huang, O., Haley, D. A., Stewart, P. L., and Horwitz, J. (1999) *Proc. Natl. Acad. Sci. U. S. A.* **96**, 6137–6142
- Kumar, L. V. S., Ramakrishna, T., and Rao, Ch. M. (1999) *J. Biol. Chem.* **274**, 24137–24141
- Perng, M. D., Muchowski, P. J., van den IJssel, P., Wu, G. J., Hutcheson, A. M., Clark, J. I., and Quinlan, R. A. (1999) *J. Biol. Chem.* **274**, 33235–33243
- Shroff, N. P., Cheria-Shaw, M., Bera, S., and Abraham, E. C. (2000) *Biochemistry* **39**, 1420–1426
- Litt, M., Kramer, P., LaMorticella, D. M., Murphy, W., Lovrien, E. W., and Weleber, R. G. (1998) *Hum. Mol. Genet.* **7**, 471–474
- Quax-Jeuken, Y., Quax, W., van Rens, G., Khan, P. M., and Bloemendal, H. (1985) *Proc. Natl. Acad. Sci. U. S. A.* **82**, 5819–5823
- Ngo, J. T., Klisak, I., Dubin, R. A., and Piatigorsky, J. (1989) *Genomics* **5**, 665–669
- de Jong, W. W., Caspers, G. J., and Leunissen, J. A. M. (1998) *Int. J. Biol. Macromol.* **22**, 151–162
- Kato, K., Shinohara, H., Kurobe, N., Goto, S., Inaguma, Y., and Ohshima, K. (1991) *Biochim. Biophys. Acta* **1080**, 173–180
- Bhat, S. P., and Nagineni, C. N. (1989) *Biochem. Biophys. Res. Commun.* **158**, 319–325
- Dubin, R. A., Warwousek, E. F., and Piatigorsky, J. (1989) *Mol. Cell. Biol.* **9**, 1083–1091
- Sun, T. X., Das, B. K., and Liang, J. J. N. (1997) *J. Biol. Chem.* **272**, 6220–6225
- Bova, M. P., Mchaourab, H. S., and Fung, B. K. K. (2000) *J. Biol. Chem.* **275**, 1035–1042
- Bennardini, F., Wrzosek, A., and Chiesi, M. (1992) *Circ. Res.* **71**, 288–294
- Djabali, K., de Néchaud, B., Landon, F., and Portier, M. (1997) *J. Cell Sci.* **110**, 2759–2769
- Scotting, P., McDermott, H., and Mayer, R. J. (1991) *FEBS Lett.* **285**, 75–79
- Renkawek, K., Voorter, C. E. M., Bosman, G. J. C. G. M., van Workum, F. P. A., and de Jong, W. W. (1994) *Acta Neuropathol.* **87**, 155–160
- Renkawek, K., de Jong, W. W., Merck, K. B., Frenken, C. W. G. M., Van Workum, F. P. A., and Bosman, G. J. C. G. M. (1992) *Acta Neuropathol.* **83**, 324–327
- Renkawek, K., Stege, G. J., and Bosman, G. J. C. G. M. (1999) *Neuroreport* **10**, 2273–2276
- De Jong, W. W., Leunissen, J. A. M., Voorter, C. E. (1993) *Mol. Biol. Evol.* **10**, 103–126
- Wistow, G., (1985) *FEBS Lett.* **181**, 1–6
- Farahbakhsh, Z. T., Huang, Q. L., Ding, L. L., Altenbach, C., Steinhoff, H. J., Horwitz, J., and Hubell, W. L. (1995) *Biochemistry* **34**, 509–516
- Smulders, R. H. P. H., van Boekel, M. A. M., and de Jong, W. W. (1998) *Int. J. Biol. Macromol.* **22**, 187–196
- Leroux, M. R., Melki, R., Gordon, B., Batelier, G., and Candido, E. P. M. (1997) *J. Biol. Chem.* **272**, 24646–24656